Sign in

ORMP on Nasdaq

Oramed Pharmaceuticals

Logo: Oramed Pharmaceuticals, Public domain, via Wikimedia Commons5

Pharmaceutical company of Israel

Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.3 Its chief executive is Nadav Kidron.1 Its shares trade on Nasdaq under the symbol ORMP.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2006Founded1

Compare with Sagimet Biosciences Inc., Cocrystal Pharma, Inc. or Lipocine Inc., or pick any stock.

  • TickerORMP on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersNew York City1
  • Founded inUnited States1
  • Websitewww.oramed.com
  • Legal formlimited company, public company1
  • Listed onNasdaq, Tel Aviv Stock Exchange (ORMP), Nasdaq (ORMP)1
  • Incorporated inDE6
  • Business address1185 Avenue Of The Americas, 3Rd Floor, New York, Ny 100366
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • LEI5299006K52ZIIGQJ6R844
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o Vcorp Services, LLC, 1013 Center Road, Suite 403-B, 19805 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 49517224

See how the biggest companies compare on our leaderboards

Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

0.7%Gross margin9
-754.4%Operating margin9
3202.5%Net margin9
32.1%Return on equity9
-$9.2MFree cash flow9

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$2.0M
  • Research and development8¢$6.4M
  • Income tax14¢$11.3M
  • Profit76¢$64.0M

Out of $2.0M in revenue.9

Financial statements

Revenue101112139$2.0M in 2025−26% since 2019
0$1.0M$2.0M$3.0M2019: $2.7M$2.7M20192020: $2.7M$2.7M2020+0%2021: $2.7M$2.7M2021−0%2022: $2.7M$2.7M2022+0%2023: $1.3M$1.3M2023−50%2025: $2.0M$2.0M2025+49%
Operating income101112139-$15.1M in 2025+3% since 2019
-$60.0M-$40.0M-$20.0M02019: -$14.6M-$14.6M20192020: -$11.8M-$11.8M2020−20%2021: -$24.2M-$24.2M2021+106%2022: -$40.6M-$40.6M2022+68%2023: -$15.8M-$15.8M2023−61%2024: -$12.8M-$12.8M2024−19%2025: -$15.1M-$15.1M2025+18%
Net income101112139$64.0M in 2025
-$50.0M0$50.0M$100.0M2019: -$14.4M-$14.4M20192020: -$11.5M-$11.5M2020−20%2021: -$23.0M-$23.0M2021+100%2022: -$36.6M-$36.6M2022+59%2023: $5.1M$5.1M20232024: -$19.1M-$19.1M20242025: $64.0M$64.0M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
REVENUES$2.0M
COST OF REVENUE-$2.0M
GROSS PROFIT$13.0K
RESEARCH AND DEVELOPMENT EXPENSES-$6.4M-$6.3M
GENERAL AND ADMINISTRATIVE EXPENSES-$8.7M-$6.5M
OPERATING LOSS-$15.1M-$12.8M
OTHER INCOME, NET$958.0K
INTEREST EXPENSES (note 12)-$853.0K
FINANCIAL INCOME (LOSS), NET (note 17)$89.5M-$2.3M
INCOME (LOSS) BEFORE TAX EXPENSES$75.3M-$15.9M
TAX EXPENSES-$11.3M-$3.2M
NET INCOME (LOSS)$64.0M-$19.1M
NON-CONTROLLING INTERESTS-$34.0K-$43.0K
COMPANYS STOCKHOLDERS$64.0M-$19.1M
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)$1.53-$0.48
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)$1.50-$0.48
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)41.4M shares40.9M shares
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)42.4M shares40.9M shares

Compare Oramed Pharmaceuticals with another company

Corporate structure

Oramed Pharmaceuticals sits at the top of its group. 6 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Oramed Pharmaceuticals

  • Aquamarine Financial (Cayman) Ltd Filed SCHEDULE 13G/A on Oramed Pharmaceuticals, latest Aug 14, 2026 (2 filings since May 15, 2026)
  • BML Investment Partners, L.P. Filed SCHEDULE 13G/A on Oramed Pharmaceuticals, latest Jun 29, 2026 (4 filings since Sep 16, 2024)
  • Nadav Kidron Filed SCHEDULE 13D/A on Oramed Pharmaceuticals, latest Aug 28, 2025 (2 filings since Mar 22, 2024)

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (4 companies). Each entity in the chart links to its source.

What it owns

What Oramed Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$586.0K9 Dec 31, 2025$698.0K9 Dec 31, 2024−16.0%
Operating-lease assets (leased space)$750.0K9 Dec 31, 2025$414.0K9 Dec 31, 2024+81.2%

Real estate and locations

ItemLatestA year beforeChange
Area of land2649 Dec 31, 202526413 Feb 1, 20220%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$45.9M9 Dec 31, 2025$54.4M9 Dec 31, 2024−15.6%
Marketable securities, current$5.4M9 Dec 31, 2025$3.4M9 Dec 31, 2024+57.4%
Marketable securities, non-current$8.4M9 Dec 31, 2025$1.8M13 Dec 31, 2023+363.3%
Equity securities at fair value$63.6M9 Dec 31, 2025$28.8M9 Dec 31, 2024+120.8%

Properties, in its own words

Our corporate headquarters is located at 1185 Avenue of the Americas, New York, NY 10036. We currently lease approximately 2,842 square feet of office space at 20 Mamilla Street, Jerusalem, Israel under a lease that expires in August 31, 2030.

We believe that our existing facilities are suitable and adequate to meet our current business requirements. In the event that we should require additional or alternative facilities, we believe that such facilities can be obtained on short notice at competitive rates.

Item 2 of the 10-K filed Mar 26, 2026.18

The story

Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.

From Wikipedia’s article on Oramed, shared under CC BY-SA 4.0.7

Leadership

Who has led Oramed Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nadav Kidron2007–now

President

  1. Nadav Kidron2007–now

Chief financial officer

  1. George Drazenovic2006
  2. Alex Weber2007
  3. Chaime Orlev2008–2009
  4. Yifat Hen Zommer2009–2017
  5. Hilla Eisenberg2017–2019
  6. Avraham Gabay2019–2021
  7. David Silberman2021–2024

Chief operating officer

  1. Joshua Hexter2013–now
2010201520202025
Board members and other officers (20)

Products and brands

Product pipeline

Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.

In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.

In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.

In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.

Read the full text

In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.

On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.

Subsidiaries

OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.

From Wikipedia’s article on Oramed, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Oratech pharmaceuticals ltd - Incorporated Israel8

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Integrated Security Technologies, Inc.Jun 14, 2004 to Apr 10, 20066
  • IGUANA VENTURES LTDNov 29, 2002 to Jun 10, 20046

Timeline

  1. Sep 17, 20268-K Shareholder vote48
  2. Jun 30, 20268-K Bylaws or fiscal year changed; Other events49
  3. Mar 31, 20268-K Entered a material agreement; Completed an acquisition or sale50
  4. Feb 20, 20268-K Entered a material agreement51
  5. Jan 14, 20268-K Entered a material agreement; Other events52
  6. Jan 7, 20268-K Other events53
  7. Dec 31, 20258-K Other events54
  8. Dec 31, 20258-K Executive or director change55
  9. Nov 17, 20258-K Entered a material agreement; Change to shareholders' rights56
  10. Nov 17, 20258-K Results of operations57
  11. Oct 24, 20258-K Entered a material agreement; Ended a material agreement; Results of operations58
  12. Oct 6, 20258-K Other events59
  13. Aug 3, 2007New chief executive Nadav Kidron becomes CEO1
  14. Apr 10, 2006Went public Listed on NASDAQ1
  15. 2006Founded Founded in United States1

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202660

When it reported results

  1. Nov 17, 2025Reported quarterly or annual results57
  2. Oct 24, 2025Reported quarterly or annual results58
  3. Nov 10, 2022Reported quarterly or annual results61

Drug trials and FDA: coming up

  1. Apr 25, 2027Phase 3 trial readout expected Phase 3 trial of ORMD-0801 8 mg and ORMD-0801 16 mg in Type 2 Diabetes Mellitus: primary completion expected Apr 25, 2027 (ClinicalTrials.gov NCT06731075).62

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

234 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 64 major events, 120 insider forms, 8 large holders, 20 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 1, 2026144 EDGAR
  4. Oct 1, 2026144 EDGAR
  5. Sep 25, 20264 EDGAR
  6. Sep 25, 20264 EDGAR
  7. Sep 25, 20264 EDGAR
  8. Sep 25, 20264 EDGAR
  9. Sep 17, 20268-K CURRENT REPORT EDGAR
  10. Aug 14, 2026SCHEDULE 13G/A EDGAR
  11. Aug 10, 202610-Q QUARTERLY REPORT EDGAR
  12. Aug 3, 2026ARS EDGAR
  13. Aug 3, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  14. Aug 3, 2026DEF 14A PROXY STATEMENT EDGAR
  15. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Jul 1, 2026144 EDGAR
  18. Jul 1, 2026144 EDGAR
  19. Jun 30, 20268-K CURRENT REPORT EDGAR
  20. Jun 29, 2026SCHEDULE 13G/A EDGAR

The 234 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 6 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2026Hexter JoshuaCOO & CBOSale137,000$4.46$611.0KForm 4
Jul 1, 2026Gabay AvrahamChief Financial OfficerSale73,360$4.51$330.9KForm 4
Apr 4, 2023Mayer ArieDirectorBuy3,800$2.21$8.4KForm 4
Apr 3, 2023Mayer ArieDirectorBuy5,009$2.22$11.1KForm 4
Mar 16, 2023KIDRON NADAVPresident and CEOBuy26,000$2.04$53.0KForm 4
Mar 14, 2023KIDRON NADAVPresident and CEOBuy100,000$2.01$201.0KForm 4
Mar 14, 2023Kidron MiriamChief Scientific OfficerSale100,000$2.01$201.0KForm 4
Mar 14, 2023Rozov YadinDirectorBuy50,000$2.05$102.5KForm 4
Mar 13, 2023Rozov YadinDirectorBuy20,000$1.96$39.2KForm 4
Jan 3, 2023Rabinowitz MichaelChief Commercial OfficerSale13,325$12.55$167.2KForm 4
Mar 21, 2022RAKIN KEVINDirectorSale10,000$9.41$94.1KForm 4
Nov 1, 2021Mayer ArieDirectorSale3,000$25.60$76.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

Oramed Pharmaceuticals has told the SEC it owns more than 5% of 4 companies, latest first (Schedules 13D and 13G).

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Nadav Kidron52$619.5K$4.8M70
2025Dr. Miriam Kidron85$439.9K$2.2M70
2025Joshua Hexter55$285.4K$1.9M70
2024PresidentChief Executive Officer and Chairman$540.1K$2.1M70
2024Chief Scientific Officer and director$408.1K$1.5M70
2024Chief Operating and Business Officer$259.0K$1.0M70

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 84. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Mercer Global Advisors Inc /adv3,810,540$18.3M0.0%+1,900,000
Aquamarine Financial (Cayman) Ltd2,512,175$12.1M0.7%+399,863
Gem Investment Advisors, LLC1,998,802$9.6M5.9%+358,733
BlackRock, Inc.1,608,111$7.7M0.0%+1,515,919
Murchinson Ltd.1,290,294$6.2M3.0%−25,000
BML Capital Management, LLC866,269$4.2M2.4%−2,300,962
Boothbay Fund Management, LLC578,638$2.8M0.1%−22,078
Geode Capital Management, LLC500,690$2.4M0.0%+476,408
Goldman Sachs Group Inc253,293$1.2M0.0%New
State Street Corp242,100$1.2M0.0%New
Rathbones Group PLC233,018$1.1M0.0%−233,018
Vanguard Portfolio Management LLC229,882$1.1M0.0%New
Dimensional Fund Advisors LP202,609$973.8K0.0%+44,400
Northern Trust Corp184,920$889.5K0.0%New
Renaissance Technologies LLC183,800$884.1K0.0%+36,100
Wells Fargo & Company/mn166,000$798.5K0.0%+8,414
Bank Of America Corp /de/150,694$724.8K0.0%+4,542
Strs Ohio133,800$643.6K0.0%New
Jane Street Group, LLC113,349$545.2K0.0%+60,809
O'shaughnessy Asset Management, LLC102,962$495.2K0.0%−13,401
Marshall Wace, Llp101,953$490.4K0.0%−157,658
Hillsdale Investment Management Inc.89,300$429.5K0.0%−8,000
Ritholtz Wealth Management84,347$405.7K0.0%−71,132
Charles Schwab Investment Management Inc83,634$402.3K0.0%New
Bank of New York Mellon Corp79,255$381.2K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jan 10, 2025Brad KnottRepublican, HouseSale$15,001 - $50,000−41.9%Report
Jan 14, 2022Andrew R. GarbarinoRepublican, HouseSale$1,001 - $15,000+128.2%Report
Oct 1, 2021Andrew R. GarbarinoRepublican, HousePartial sale$1,001 - $15,000+157.8%Report
Apr 23, 2021Andrew R. GarbarinoRepublican, HouseBuy$1,001 - $15,000−142.5%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Oramed Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARORAMED PHARMACEUTICALS INC.2
  • CIK0001176309
  • Employer ID (EIN)98-037600818
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company18
  • Incorporated inDelaware18
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address1185 Avenue Of The Americas, 3Rd Floor, New York, NY 100362
  • Phone646-844-11642
  • Shares outstanding41,597,354 as of Aug 10, 202615
  • Public float$77.7M as of Jun 30, 202518
  • AuditorKesselman & Kesselman C.P.A.s, Tel Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting18
  • On EDGAR sinceNov 29, 20022
  • Filings941 in all: 8-K (264), 4 (251), 10-Q (54), 424B3 (40), 3 (37), 10-K (17), SC 13G/A (17), 10QSB (16)2
    All 57 form types

    424B5 (16), DEF 14A (15), EFFECT (15), UPLOAD (14), SC 13G (13), CORRESP (11), SC 13D (9), 4/A (8), 424B7 (8), NT 10-Q (8), S-8 (8), SCHEDULE 13G/A (8), ARS (7), CT ORDER (7), S-3 (7), SC 13D/A (7), 10KSB (6), PRE 14A (6), D (5), S-1 (5), SB-2/A (5), 10QSB/A (4), 144 (4), D/A (4), NT 10-K (4), POS AM (4), SCHEDULE 13D/A (4), 8-K/A (3), SCHEDULE 13D (3), 10-K/A (2), 10KSB/A (2), 8-A12B (2), REGDEX (2), S-1/A (2), SB-2 (2), SCHEDULE 13G (2), 10-Q/A (1), 10-QT (1), 3/A (1), 5 (1), 8-A12G (1), CERTNAS (1), DEFA14A (1), FWP (1), NTN 10Q (1), PRER14A (1), RW (1), S-3MEF (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Aug 3, 2026
    Latest 8-K (8-K) Sep 17, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.012ORMPNasdaq

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).18

Risk factors and legal proceedings

The risks Oramed Pharmaceuticals names in Item 1A of its 10-K filed Mar 26, 2026: 43 risks under these headings, as written.18

  • Risks Related to Our Business
  • Risks Related to our Common Stock
  • Risks Related to Conducting Business in Israel
  • General Risk Factors
  • Our strategic review process may not be successful or timely.
  • If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks.
  • Our ability to consummate a strategic transaction depends on our ability to retain our employees required to consummate such transaction.
  • We may become involved in securities and stockholder litigation that could divert management’s attention and harm the Company’s business, and insurance coverage may not be sufficient to cover all costs and damages.
  • We have a history of losses and may not be able to sustain profitability in the future.
  • We may need substantial additional capital in order to satisfy our business objectives.
  • We have a history of losses and can provide no assurance as to our future operating results.
  • We rely upon patents to protect our technology.
The other 35 risks
  • We may be unable to protect our intellectual property rights and we may be liable for infringing the intellectual property rights of others.
  • Even if we succeed in commencing a new clinical trial for our oral insulin capsule, there are a variety of risks and uncertainties related to its development.
  • We have limited experience in conducting clinical trials.
  • Our clinical trials may encounter delays, suspensions or other problems.
  • Initial success in the completed and ongoing early-stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.
  • We can provide no assurance that our products will obtain regulatory approval or that the results of clinical trials will be favorable.
  • We are dependent upon third party suppliers of our raw materials and for other services.
  • We may not realize a return on the shares of DNA, Entera, Nano, Alpha Tau and Pelthos that we own.
  • Because we may from time to time maintain a significant percentage of our assets in cash and/or securities, we may in the future be deemed to be an investment company under the Investment Company Act of 1940 resulting in additional costs and regulatory burdens.
  • We may not realize the full benefit from our distribution license agreement with Medicox.
  • We are highly dependent upon our ability to enter into agreements with collaborative partners to develop, commercialize and market our products.
  • The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.
  • Our financial position or results could be negatively affected by product liability claims.
  • We have limited senior management resources and may be required to obtain more resources to manage our growth.
  • We depend upon our senior management and skilled personnel and their loss or unavailability could put us at a competitive disadvantage.
  • Our existing and any future joint ventures may limit our flexibility with jointly owned investments and we may not realize the benefits we expect from these arrangements.
  • Healthcare policy changes, including pending legislation recently adopted and further proposals still pending to reform the U.S. healthcare system, may harm our future business.
  • We are exposed to fluctuations in currency exchange rates.
  • Our investments in real estate may expose us to market and liquidity risks that could adversely affect our financial condition and results of operations
  • If Alpha Tau fails to achieve positive clinical results or obtain regulatory approvals, the value of our investment could decline materially, which may adversely affect our financial results.
  • We have lent a substantial amount of funds to Scilex. In the event that Scilex is unable to service its obligations under the Note and defaults on such Note, it could have a material adverse effect on our business.
  • The value of our investment into Lifeward may decline.
  • Future sales of our common stock by our existing stockholders could adversely affect our stock price.
  • Our issuance of warrants, options and RSUs to investors, employees and consultants may have a negative effect on the trading prices of our common stock as well as a dilutive effect.
  • Our failure to maintain compliance with the Nasdaq Capital Market’s continued listing requirements could result in the delisting of our common stock.
  • As the market price of our common stock may fluctuate significantly, this may make it difficult for you to sell your shares of common stock when you want or at prices you find attractive.
  • Future sales of common stock or the issuance of securities senior to our common stock or convertible into, or exchangeable or exercisable for, our common stock could materially adversely affect the trading price of our common stock, and our ability to raise funds in new equity offerings.
  • Our stockholders may experience significant dilution as a result of any additional financing using our equity securities.
  • We are affected by the political, economic and military risks of having operations in Israel.
  • It may be difficult to enforce a U.S. judgment against us or our officers and directors and to assert U.S. securities laws claims in Israel.
  • Changes to tax laws could have a negative effect on us or our stockholders.
  • Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.
  • Our management will have significant flexibility in using the net proceeds of any offering of securities.
  • Our stockholder rights plan, or “poison pill,” includes terms and conditions which could discourage a takeover or other transaction that stockholders may consider favorable.
  • Delaware law could discourage a change in control, or an acquisition of us by a third party, even if the acquisition would be favorable to you, and thereby adversely affect existing stockholders.

Legal proceedings

From time to time, we are a party to litigation and subject to claims incident to the ordinary course of business. Future litigation may be necessary to defend ourselves by determining the scope, enforceability, and validity of third-party proprietary rights or to establish our proprietary rights.

The opening of Item 3, Legal Proceedings.18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
    SEC EDGAROther events
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
    SEC EDGAROther events
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70